111,039 Shares of Boston Scientific Corporation $BSX Acquired by First Nebraska Trust Co

First Nebraska Trust Co acquired a new position in Boston Scientific Corporation (NYSE:BSX) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 111,039 shares of the medical equipment provider’s stock, valued at approximately $4,847,000.

Several other institutional investors have also recently made changes to their positions in the business. BlackRock Inc. purchased a new stake in Boston Scientific during the 2nd quarter valued at approximately $5,534,781,000. Primecap Management Co. CA bought a new stake in shares of Boston Scientific in the second quarter worth about $2,156,233,000. Janus Henderson Group PLC boosted its stake in Boston Scientific by 31.0% during the first quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock valued at $1,035,202,000 after buying an additional 3,907,981 shares during the last quarter. Amundi grew its holdings in Boston Scientific by 13.8% during the 1st quarter. Amundi now owns 14,122,913 shares of the medical equipment provider’s stock valued at $886,213,000 after buying an additional 1,707,754 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its stake in Boston Scientific by 25.9% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider’s stock worth $871,702,000 after acquiring an additional 2,856,040 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Down 1.7%

Shares of NYSE BSX opened at $43.58 on Wednesday. Boston Scientific Corporation has a 1 year low of $39.57 and a 1 year high of $105.65. The firm has a 50-day simple moving average of $44.55 and a two-hundred day simple moving average of $56.38. The company has a market cap of $63.15 billion, a P/E ratio of 18.47, a PEG ratio of 1.29 and a beta of 0.60. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, meeting analysts’ consensus estimates of $0.73. Boston Scientific had a return on equity of 18.73% and a net margin of 16.62%. The firm had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. During the same quarter in the prior year, the firm posted $0.75 earnings per share. The company’s quarterly revenue was up 1.4% on a year-over-year basis. Research analysts anticipate that Boston Scientific Corporation will post 3.17 earnings per share for the current year.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported that the SIMPLAAFY trial of its WATCHMAN FLX Pro heart device met its six-month primary endpoints. The results found two post-implant drug regimens non-inferior to dual-antiplatelet therapy, potentially supporting simpler treatment after the procedure. Article: SIMPLAAFY study results
• Neutral Sentiment: Boston Scientific and Blackstone Life Sciences announced a $455 million collaboration to co-develop the VITALYST heart-pump technology. The arrangement may ease near-term development costs, but an analyst noted it could defer growth and leave longer-term uncertainty. Article: VITALYST collaboration Article: Analyst assessment of VITALYST deal
• Negative Sentiment: A Zacks analysis flagged weakening earnings estimates, softer momentum in core businesses and major growth catalysts that may not arrive until 2028. Those concerns could overshadow the company’s valuation discount. Article: Valuation and earnings-growth analysis
• Negative Sentiment: J.P. Morgan maintained a Hold rating, while TD Cowen also cut its rating to Hold; Barclays lowered its price target. The cautious analyst stance adds to concerns about near-term growth. Article: J.P. Morgan rating Article: TD Cowen rating Article: Barclays price-target change

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Mizuho set a $50.00 price objective on Boston Scientific in a report on Thursday, October 29th. Sanford C. Bernstein reduced their price target on shares of Boston Scientific from $54.00 to $49.00 and set an “outperform” rating on the stock in a research report on Thursday, October 29th. Deutsche Bank Aktiengesellschaft set a $48.00 price target on shares of Boston Scientific and gave the company a “buy” rating in a research note on Thursday, October 29th. Robert W. Baird upped their price target on shares of Boston Scientific from $50.00 to $51.00 and gave the company an “outperform” rating in a research note on Thursday, October 29th. Finally, Truist Financial lowered their price objective on shares of Boston Scientific from $57.00 to $51.00 and set a “buy” rating for the company in a research report on Wednesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $61.43.

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.